Protein kinase B (Akt) plays a major role in the regulation of breast cancer growth, survival, hormone, drug and radiosensitivity, but the clinical value of its expression and activation in human tumors is unclear. Activated Akt1 (pAkt1) expression was quantified in a series of 46 breast cancer and adjacent mammary gland samples by a direct Path-Scan TM PhosphoAkt1 (Ser473) sandwich ELISA kit. VEGF, sVEGFR1 and sVEGFR2 levels were measured simultaneously by standard ELISA kits. Forty-nine percent of the tumors had an increased pAkt1 level as compared to adjacent tissue. pAkt1 levels were significantly higher in stage IIb than in stage I-IIa tumors. The frequency of pAkt1 elevation was positively associated with tumor size and malignancy grade. pAkt1 was also twice as frequently increased in PgR-negative as in PgR-positive tumors, while its mean level was significantly higher in ER-positive than in ER-negative tumors. VEGF, sVEGFR1 and sVEGFR2 were increased in 73-85% of the tumors, but no associations with most clinicobiological factors and pAkt1 level were found. In conclusion, activation of Akt1 is not associated with VEGF signaling protein expression in breast cancer but is related to tumor size, grade of malignancy, and steroid receptor status. (Int J Biol Markers 2006; 21: 12-9)
INTRODUCTION
The serine/threonine kinase Akt or protein kinase B controls many of the intracellular processes that are dysregulated in human cancer (1, 2) . It has particularly become a focus of interest because of its ability to inhibit apoptosis and mediate cell survival by acting as a transducer of signals from growth factor receptors, especially erbB-2, that activate phosphatidylinositol 3-kinase (PI3K) (3) (4) (5) (6) . Being a common signaling pathway for various oncogenes and tumor suppressor genes, Akt is also involved in VEGF regulation by participating in the induction of HIF-1 -the main transcriptional activator of VEGF synthesis (7-9) -and transducing the VEGF-VEGF receptor signal (10) . Recently it was shown that VEGF is not only the key activator of tumor angiogenesis and regulator of endothelial cell growth, but also acts as a survival factor for breast cancer cells by inhibiting tumor cell apoptosis (11) .
The Akt kinase was also shown to be a downstream effector of estrogen-dependent proliferation and survival in hormone-responsive breast carcinoma cells: estradiol can rapidly activate PI3K/Akt in hormone-dependent MCF-7 cells, and this activation requires the estrogen receptor (ER) alpha (12) . On the other hand, Akt phosphorylation is significantly increased in tamoxifen-resistant MCF-7 cells under basal conditions (13) , and phosphorylated Akt can activate ER alpha in the absence of estrogen (14) via direct phosphorylation while Akt-induced ER alpha activity is not inhibited by tamoxifen (15) , implicating that this pathway might contribute to breast cancer hormone resistance.
Although experimental data on the role of PI3K/Akt pathway in the regulation of breast cancer growth, survival, hormone, drug and radiosensitivity are abundant (see [16] [17] [18] [19] for review), and these signaling proteins are now regarded as prospective molecular targets for improvement of breast cancer therapies (20) (21) (22) , the papers describing Akt expression and/or activation in clinical samples are rather equivocal (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , and the role of the PI3K/Akt system in the clinical course of human breast cancer is still unclear. There are practically no data concerning interrelationships between PI3K/Akt and VEGF signaling molecules in human breast cancer tissue.
We demonstrated in a previous study that PI3K expression was increased in the majority of breast cancers with various grades of malignancy and hormone sensitivity (35) . In the present study we have examined by a specific quantitative enzyme-linked immunosorbent assay (ELISA) the activated Akt1/PKBa expression in a series of breast cancer and adjacent mammary gland samples collected at surgery. Preliminary analysis revealed an elevation of pAkt1 levels in ER-positive tumors (36) , and here we present a detailed evaluation of the associations between Akt1 phosphorylation and clinicopathological data, tumor steroid receptor status, as well as tissue VEGF and its type 1 (VEGFR1) and type 2 (VEGFR2) receptor levels.
MATERIALS AND METHODS

Patients and tissues
Tumor and adjacent histologically unchanged mammary gland samples from 46 breast cancer patients were collected by a pathologist during routine intraoperative examination of the dissected gland, then frozen in liquid nitrogen, and stored at -70°C until processed. The study design met the requirements of the Ethical Committee of the Russian N.N. Blokhin Cancer Research Center.
The patients' age ranged from 35 to 75 years; 21 patients were lymph node negative and the remaining 25 had various degrees of lymph node involvement. Thirteen patients received pre-surgical therapy (seven chemotherapy and six radiotherapy). Tumor histology was assessed by one and the same pathologist according to the WHO guidelines: about half of the tumors (24) belonged to the invasive ductal type, six to the invasive lobular type and in six tumors both types were coexistent; there were singular samples of tubular, mucinous and papillary carcinoma. Two tumors were attributed to grade I, 12 to grade II and 20 to grade III. In the remaining tumors marked post-therapeutic changes were revealed.
Tumor estrogen receptor (ER) and progesterone receptor (PgR) content was detected in tissue cytosols (105,000xg supernatants) by standardized radioligand dextran-coated charcoal (DCC) assay as previously described (37) . Quality control was carried out in collaboration with the Receptor and Biomarker Study Group of the European Organization for Research and Treatment of Cancer. The cutoff value for both ER and PgR was 10 fmol/mg protein.
Preparation of tissue extracts for ELISA procedures
Tissue samples were pulverized in liquid nitrogen and lysed in a three-fold volume of 20 mM Tris-HCP (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM βglycerophosphate, 1 mM sodium orto-vanadate, 1 µg/mL leupeptin, and then centrifuged at 20,000g, 4°C for 30 min (Optima TM TLX, Beckman, USA). Supernatants were collected and stored in aliquots at -70°C until assayed.
ELISA of phosphorylated Akt1 level
A direct PathScan™ Phospho-Akt1 (Ser473) sandwich ELISA kit (Cell Signaling Technology, Inc., Beverly, MA, USA) was used for the assessment of activated Akt1 level. This kit detects endogenous levels of Akt1 only when phosphorylated at serine 473. Its sensitivity for recombinant pAkt1 (Ser473) according to the manufacturer's information comprises 62.5-125 pg. It does not detect Akt phosphorylated at other sites or related kinases such as PKC and p70 S6 kinase. The principle of the procedure is the following: a Phospho-Akt (Ser473) antibody (#9271) is coated onto the microwells. After incubation with tissue lysates, the pAkt protein is captured by this coated antibody, and following extensive washing Akt1 (2H10) monoclonal antibody (#2967) is added to detect the captured Phospho-Akt1 protein. Horseradish peroxidase (HRP)-linked anti-mouse antibody is then used to recognize the bound detection antibody, and after incubation with HRP substrate, TMB, the optical density (OD450) for the developed color is measured, its magnitude being proportional to the quantity of phosphorylated Akt1 protein. The latter was expressed in relative optical units (u = 10xOD450) per 1 mg of total protein in tissue extract.
ELISA procedures for VEGF, sVEGFR1 and sVEGFR2
VEGF, sVEGFR1 and sVEGFR2 levels were measured by the following standard direct enzyme immunoassay kits: Human VEGF ELISA (BioSource International, Inc., Camarillo, CA, USA), Human sVEGF-R1 ELISA (Bender MedSystems, Vienna, Austria), and Quantikine ® Human sVEGF R2 Immunoassay (R&D Systems, Minneapolis, MN, USA), respectively. All the measurements were conducted according to the methods recommended by the manufacturers, and the results were read on an ELX800 microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA). All analyte concentrations were normalized by total protein content in the lysates quantified by the Lowry assay.
Statistics
Quantitative parameters were compared using the nonparametric Mann-Whitney, median and sign tests. Correlations between quantitative parameters were explored by the Pearson test (r). Associations between groups were assessed by Spearman's rank correlation (R) and gamma correlation (γ) tests. A p value of <0.05 was considered statistically significant in all tests.
RESULTS
pAkt1, VEGF, sVEGFR1, and sVEGFR2 concentrations in breast tumors and adjacent tissues
Measurable levels of pAkt1 were detected by the specific ELISA kit in all breast cancer and adjacent mammary gland samples. We also found detectable and widely variable levels of VEGF and sVEGFR1 in all tumor and non-cancerous samples, and there was only one "normal" mammary gland sample with unmeasurable sVEGFR2. All protein levels except those of pAkt1 were highly significantly elevated in tumors compared to adjacent tissues in 73-85% of the patients as revealed by the sign test (Tab. I). pAkt1 was elevated in only 49% of the tumors, and the difference between breast cancer and adjacent tissue was not statistically significant.
Tumor pAkt1 levels were positively correlated with corresponding "normal" tissue values (r = 0.5; p<0.0001), but VEGF and its receptor concentrations in the tumors and adjacent tissues were not significantly associated.
Significant positive correlations were observed between VEGF and sVEGFR1 (r = 0.40; p = 0.01) as well as between VEGF and sVEGFR2 (r = 0.48; p = 0.002). Nonetheless, sVEGFR1 and sVEGFR2 concentrations were not significantly associated with one another. No associations were found between VEGF or sVEGFR and pAkt1 concentrations.
Clinicopathological correlations
The relationships between the ELISA-detected levels of pAkt1 and VEGF-signaling system components are presented in Table II . We also present the data on the frequency of pAkt1 elevation in tumor as compared to adjacent tissue depending on clinicopathological characteristics. The associations between VEGF/VEGFR prevalence and clinicopathological factors were not analyzed because all these markers were elevated in most tumors (see Tab. I).
The activated Akt1 level was significantly higher in stage IIb than in stage I-IIa breast cancer samples (p<0.05), and was more frequently elevated in large (>5 cm) than in small tumors (71% and 42%, respectively; γ = 0.54, p<0.05). It was also more frequently elevated in grade III than in grade II tumors (57% vs 15%; γ = 0.50; p<0.01).
Phosphorylated Akt1 level was also significantly higher in PgR-negative than in PgR-positive tumors (p<0.05), and increased pAkt1 in tumor compared to adjacent tissue was found in 59% of PgR-negative and only in 30% of PgR-positive breast cancers (γ = -0.53, p<0.01). On the other hand, the mean pAkt1 level was significantly higher in ER-positive than in ER-negative breast cancer samples (0.64 ± 0.12 and 0.35 ± 0.04 u/mg protein, respectively; p<0.05; Student's t test).
Among the VEGF-signaling proteins only the sVEGFR2 concentration was associated with breast cancer receptor status: it was significantly higher in PgR-negative than in PgR-positive tumors (p<0.05; Mann-Whitney test), but this parameter was not associated with any other of the clinicopathological factors listed in Table II . The VEGF concentration decreased with disease stage (p<0.05), and accordingly was higher in small (≤5 cm) than in larger tumors as well as in node-negative than in node-positive cancers (p<0.05, in both cases). Nodenegative samples were also characterized by higher sVEGFR1 levels than node-positive ones (p<0.05). No other clinicopathological correlations were found. might be a necessary prerequisite for oncogenic transformation of the mammary gland (38, 39) . In recent years many authors have published data indicating a critical role of Akt activation (imposed by its phosphorylation) in conferring broad-spectrum chemoresistance (17), includ-ing resistance to tamoxifen (14) or herceptin (16) , and radioresistance (6, 21) on breast cancer cells. The Akt signaling pathway has thus been accepted and actively explored as a novel molecular target for therapies that might help to overcome resistance to known therapeutic (20) (21) (22) . Much less is known about the expression and activation state of Akt in human breast cancer tissue and its role in disease prognosis and treatment sensitivity. Three mammalian isoforms of Akt have been identified (Akt1/PKBα, Akt2/PKBβ, Akt3/PKBγ) that are similar in biological activity but differ in structure and tissue distribution. Hence, the available publications differ not only by the methods used but also by the isoforms studied. Total Akt1 and/or Akt2 was evaluated in five studies (3, 15, (23) (24) (25) , Akt 3 or all three isoforms in three studies (26) (27) (28) , and activated Akt (pAkt) in nine studies (23, 24, 26, (29) (30) (31) (32) (33) (34) . Most authors used immunostaining for various Akt isoforms and/or phosphorylated Akt (4, 16, 23, 24, 26, (29) (30) (31) (32) . Southern-blot analysis (25) and semiquantitative RT-PCR (27, 28) were also applied. Some investigators verified the results with western blot analysis (16, 23, 28) and by measuring Akt kinase activities (23, 28) .
DISCUSSION
Studies on cell cultures have demonstrated that the activation of the PI3K/Akt signal transduction pathway
Four research groups have already demonstrated the independent unfavorable prognostic value of elevated pAkt for breast cancer outcome in a random group (30) and in various subsets of patients, namely patients receiving endocrine or radiotherapy (24, 26) , node-negative patients (31, 32) and patients with HER2-overexpressing tumors (33) . By contrast, Panigrahi et al did not find any prognostic significance for pAkt (34) .
All these rather diverse but promising clinical data prompted us to further explore the role of Akt activation in clinical breast cancer. To our knowledge, this is the first study where a direct sandwich ELISA kit specific for Akt1 phosphorylated at Ser473 was used to compare the activation state of this kinase in tumors and adjacent tissues of breast cancer patients, and the second publication where quantitative data on pAkt levels in breast cancer tissue are presented. In the quantitative study, published in 2005, a chemiluminescence-linked immunosorbent assay (CLISA) for pAkt was used that differs from the method applied by us not only by the principle of detection but also by the specificity of pAkt isoforms measured (33) : while in the CLISA system described in this paper all three Akt isoforms were detected, the design of the PathScan kit allowed us to measure specifically pAkt1.
For the interpretation of the results we assessed two parameters: the tumor pAkt1 level and the frequency of its elevation in tumor as compared to adjacent mammary gland tissue. Measurable pAkt1 was detected in all tissues studied, and this corresponds with the immunohistochemical data demonstrating positive staining of basal cells of ductal structures for Akt1 of Stal et al (26) and with the semiquantitative RT-PCR data of Zinda et al (27) .The range and median values of pAkt1 in our study (Tab. I) were higher than those for total pAkt (0-1.08 u/mg protein; median 0.17 u/mg) described in the work by Cicenas et al (33) . However, direct quantitative comparisons are hardly valuable because in our case the units just corresponded with OD450 values, and Cicenas et al used their own conditional units matching the amount of pAkt extracted from a constant amount of MCF-7 cells.
About one half (49%) of the 46 tumors included in our study were characterized by an increased pAkt1 level as compared to adjacent histologically unchanged mammary gland. No quantitative comparisons of "normal" and tumor tissues were made in Cicenas' study (33) , but significantly increased Akt1 kinase activity was detected in 38% of primary breast carcinomas, and these results were confirmed by western blot and immunohistochemical staining in the work by Sun et al (23) . In other studies pAkt staining was demonstrated in about 50% (24, 26) , 65% (31) and 81% (30) of invasive breast cancers, and in a recent immunohistochemical study (29) it was shown that Akt phosphorylation increased progressively from normal breast epithelium to hyperplasia, abnormal hyperplasia, and invasive tumors. All these data correspond to the total pAkt.
The frequency of pAkt1 elevation in our study was positively associated with the grade of tumor malignancy: increased pAkt1 was almost fourfold more often observed in grade III than in grade II tumors, which coincides with the data of Sun et al (23) and their earlier data for Akt2 (15) . It was also higher in advanced than in early stage breast cancer, which is also in agreement with published data (23, 30) . On the other hand, Cicenas et al (33) using quantitative CLISA as well as some other authors (24, 26, 31) did not find any association of pAkt or Akt1 with any clinicopathological features.
Comparison with steroid receptor content determined by radioligand technique has shown that the pAkt1 level was weakly but significantly positively associated with ER status (γ=0.34; p<0.05), the mean Akt1 phosphorylation level in ER-positive tumors being higher than in ER-negative tumors. This apparently disagrees with the data of other authors, who failed to demonstrate any significant association of pAkt (24, 26, 30, 31, 33) or total Akt1 (26, 28) with ER status (all these authors, except (33), used immunohistochemistry for ER evaluation). On the other hand, increased pAkt1 in ER-positive tumors corresponds with the recently described non-genomic effect of ER alpha, which can bind in a ligand-dependent manner to the regulatory subunit of PI3K, thereby increasing its activity; this leads to the activation of Akt (40) . The counter effect was also demonstrated (13, 17) : it was shown that activated Akt can directly phosphorylate ER alpha in vitro and in vivo even in the absence of estrogen, and Akt-induced ER alpha activity was not inhibited by tamoxifen. This implies that Akt-activated ER alpha could contribute to tamoxifen resistance, possibly by protecting breast cancer cells from tamoxifen-induced apoptosis.
Contrary to what was seen with ER, in PgR-positive tumors the median pAkt1 level was 1.35 times lower than in PgR-negative tumors, and increased tumor pAkt1 was found twice as frequently in PgR-negative as in PgRpositive tumors. The highest tumor pAkt1 levels and the highest frequency of its elevation (62.5%) were registered in ER-positive/PgR-negative samples, although the differences between the various receptor status groups were not statistically significant. Thus, contradictory relationships were observed in our study between pAkt1 and the two types of steroid receptors. However, the increased pAkt1 in PgR-negative tumors might indicate impaired ER functional activity imposed by Akt kinase activation. This assumption indirectly corresponds with the data of Stal et al (26) , who demonstrated that ER-positive patients with a negative Akt status (no overexpression of Akt1, Akt2 or pAkt) were more sensitive to tamoxifen than ER-positive and Akt-positive patients. It is also substantiated by experimental data indicating that, although constitutively active PI3K and Akt induce ER activity, they reduce PgR levels and activity in cultured breast cancer cells (41) . Evaluation and modulation of PI3K/Akt signaling might therefore be considered as one of the approaches to overcome initial or acquired hormone resistance of ER-positive breast cancer.
Rather unexpectedly, the results of pAkt1 measurement disagree with those of our previous study (35) where we assessed by western blotting the expression of the regulatory p85 subunit of PI3K -the first component of the PI3K/Akt signaling pathway -and demonstrated that it was elevated in about 80% of breast cancers (almost twice more frequently than pAkt1); this elevation was not related to any of the clinicopathological factors including steroid receptors. This inconsistency might either reflect the different regulation and role of two components of one signaling system in clinical breast cancer, or might be imposed by the fact that in the former case (PI3K) we measured the basal expression of the enzyme's regulatory subunit, and in the latter (Akt1) the activated phosphoprotein level. Another explanation could be that Akt phosphorylation at Ser473 requires other regulatory proteins besides PI3K (42) .
In a number of studies the association of Akt (pAkt) expression with other molecular markers involved in multiple signaling pathways regulated by this kinase was investigated. Akt expression was found to be significantly associated with a decreased rate of apoptosis (31) but with increased cytoplasmic p53 expression (30) , lower Sphase fraction, (24), thymidylate synthase (33) and focal adhesion kinase (32) expression levels, and it was not associated with Bcl-2 (24) . pAkt expression was most frequently compared with HER2 (erbB-2) immunostaining, reflecting the widely accepted and experimentally proven role of the HER2 pathway in Akt activation on the one hand (38, 43) , and suppression of anti-HER2 antibody's inhibitory action in the cells with constitutively activated Akt on the other (17, 44) . Nevertheless, only a few authors have found a positive association between pAkt and HER2 (erbB-2) overexpression (3, 26, 29, 31) , while others failed to demonstrate such a relationship (24, 30, 33) .
In this study we compared the quantitatively measured pAkt1 expression in breast cancer tissues with the corresponding ELISA data on VEGF signaling system components. The reason for such comparison was the recently demonstrated role of the Akt/PI3K pathway in VEGF regulation and signaling not only in endothelial but also directly in breast cancer cells (7) (8) (9) (10) (11) , as well as our own preliminary data indicating that coordinate activation of Akt/PKB and VEGF signaling pathways in tamoxifen-resistant breast cancer cells might participate in the maintenance of tumor cell growth and survival by an autocrine mechanism (45) . We have demonstrated in this study that both VEGF and its type 1 and 2 receptor levels were highly significantly elevated in 73-85% of the tumors as compared to adjacent mammary gland tissue. However, no associations were found with most of the clinicopathological factors, except a paradoxical increase in VEGF level in early stage tumors and elevation of sVEGFR2 in PgR-positive samples. Interestingly, both sVEGFR1 and sVEGFR2 levels were positively correlated with VEGF, but were not associated with one another. Our observations concerning tumor sVEGFR1 partially coincide with the data of Toi et al (46) , who also found a positive association between VEGF and sVEGFR1 concentrations in breast cancer tissue and no significant correlations of these parameters with any of the clinicopathological factors. Importantly, a positive association between VEGF-A and sVEGFR1 levels was also demonstrated in blood serum (47) , although, as opposed to VEGF-A, the receptor level was not elevated in breast cancer patients compared to the control group.
Due to peculiarities of tissue processing for biochemical investigations we cannot clearly attribute the levels of the measured analytes (especially sVEGFR) exclusively to tumor cells; nevertheless, the relationships observed between the expression of VEGF and its receptors in tumor tissue may be regarded as an indirect confirmation of the tumor origin of detected VEGFR. This speculation is also based on the hypothesis that the assays developed for the determination of soluble fragments of VEGFR1 and VEGFR2 in blood serum should measure both truncated and full-size receptors when applied to tissue extracts. It is also partially supported by the data of Ryden et al (48) , who demonstrated by means of immunohistochemistry a correlation between VEGFR2 and VEGF expression, indicating that VEGF and VEGFR2 may be coexpressed in breast cancer cells.
Nevertheless, we failed to demonstrate in a clinical tissue model any significant relationships between the level of Akt1 phosphorylation and the expression of VEGF signaling components. This apparently reflects the fact that Akt1 is involved in many signaling pathways besides the one controlled by VEGF.
Quantitative ELISA detected comparable levels of pAkt1 in tumor and adjacent mammary gland tissues. The activated Akt1 kinase level in human breast cancer tissue was not associated with the expression of VEGF signaling system components but was controversially related to steroid hormone receptor status. It was also increased in advanced tumors with a high malignancy grade. Further follow-up and enlargement of the patient group are planned in order to clarify whether the activity of either of these signaling systems is related to the sensitivity of breast cancer patients to various types of endocrine therapy or to the prognosis of breast cancer in general.
